



Meet Senzime during June

Senzime to Participate in Jefferies 2018 Healthcare Conference in New York

Press Release: Uppsala, May 24, 2018, Senzime AB (SEZI), developer of unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery, today announced that its CEO, Lena Söderström, will be attending at the Jefferies Global Healthcare Conference at the Grand Hyatt New York, June 5-8, 2018.

Lena Söderström, Senzime's CEO, will be representing the company and hosting one-on-one meetings during the conference. To schedule a meeting with Mrs. Söderström, please contact lena.soderstrom@senzime.com.

Senzime to present at Småbolagsdagen, held in Stockholm, June 11

Senzime will present at Småbolagsdagen, a small-cap investor conference, held in Stockholm on June 11 (Sheraton Stockholm Hotel). The event is arranged by Aktiespararna and the company will be represented by CEO Lena Söderström.

This event is webcasted on www.smabolagsdagen.net. The presentation will be available on the company's website after the presentation.

For full program and registration, see [link](#).

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com